Literature DB >> 24445091

Is there a need for MRI within 24 hours after CT-guided percutaneous thermoablation of the liver?

Kristina Imeen Ringe1, Frank Wacker2, Hans-Jürgen Raatschen2.   

Abstract

BACKGROUND: Radiofrequency (RFA) and microwave ablation (MWA) are established minimally invasive techniques for treatment of hepatic tumors.
PURPOSE: To compare technical success and accuracy of hepatic thermoablation using computed tomography (CT) and magnetic resonance imaging (MRI) acquired 24 h after ablation with regard to evaluation of the post-interventional ablation zone and local tumor recurrence (LTR), and to assess whether additional MRI within 24 h is beneficial.
MATERIAL AND METHODS: Thirty-two patients (23 men, 9 women; mean age, 60 years) with 48 lesions were included in this retrospective study. CT was performed immediately and MRI was performed 24 h after ablation. Diameter and volume calculations of the ablation zone were compared (T-Test). Technical success and ablation margin distinction, shape, and configuration were evaluated (κ-statistic). Local effectiveness was calculated based on follow-up imaging. Technical success and ablation margin features were correlated with LTR (log-rank test, Fisher's exact test).
RESULTS: Ablation zone volumes were significantly higher with MRI compared to CT (P < 0.05; mean volume, 55.19 and 45.97 mL). Agreement between CT and MRI for technical success was good (κ = 0.801) and for margin conspicuity fair (κ = 0.289). LTR was 26.1% (mean follow-up, 11.7 months). LTR showed no correlation with technical success or margin conspicuity.
CONCLUSION: CT and MRI are suited for early evaluation of technical success after thermoablation. Within 24 h a significant increase of the ablation volume is observed, which has to be taken into account when interpreting immediate postprocedural imaging and treating lesions near critical structures. Additional MRI 24 h after ablation seems of limited value regarding prognosis of LTR, especially with regards to evaluation of ablation margin shape and conspicuity. © The Foundation Acta Radiologica 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Radiofrequency ablation (RFA); microwave ablation (MWA); tumor recurrence

Mesh:

Year:  2014        PMID: 24445091     DOI: 10.1177/0284185114520858

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  6 in total

1.  18F-FDG PET/CT Is an Immediate Imaging Biomarker of Treatment Success After Liver Metastasis Ablation.

Authors:  Francois Cornelis; Vlasios Sotirchos; Elena Violari; Constantinos T Sofocleous; Heiko Schoder; Jeremy C Durack; Robert H Siegelbaum; Majid Maybody; John Humm; Stephen B Solomon
Journal:  J Nucl Med       Date:  2016-02-23       Impact factor: 10.057

2.  Perivascular parenchymal extension of the ablation zone following liver microwave ablation.

Authors:  Saurabh Singh; Pulathis Nilantha Siriwardana; Edward William Johnston; Steven Bandula; Brian Ritchie Davidson; Rowland Oliver Illing
Journal:  BMJ Case Rep       Date:  2016-03-31

Review 3.  Magnetic Resonance Image-Guided Focal Prostate Ablation.

Authors:  Sherif G Nour
Journal:  Semin Intervent Radiol       Date:  2016-09       Impact factor: 1.513

Review 4.  [Radiological diagnostic workup of liver tumors].

Authors:  H-J Raatschen
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

5.  A Review of Imaging Methods to Assess Ultrasound-Mediated Ablation.

Authors:  Brett Z Fite; James Wang; Pejman Ghanouni; Katherine W Ferrara
Journal:  BME Front       Date:  2022-05-02

6.  Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma.

Authors:  Robert Peter Reimer; Nils Große Hokamp; Julius Niehoff; David Zopfs; Simon Lennartz; Mariam Heidar; Roger Wahba; Dirk Stippel; David Maintz; Daniel Pinto Dos Santos; Christian Wybranski
Journal:  PLoS One       Date:  2021-06-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.